94 related articles for article (PubMed ID: 15503027)
1. Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies.
Chen X; Bies RR; Ramanathan RK; Zuhowski EG; Trump DL; Egorin MJ
Cancer Chemother Pharmacol; 2005 Mar; 55(3):237-43. PubMed ID: 15503027
[TBL] [Abstract][Full Text] [Related]
2. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL
Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
[TBL] [Abstract][Full Text] [Related]
3. Biliary excretion of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats.
Musser SM; Egorin MJ; Zuhowski EG; Hamburger DR; Parise RA; Covey JM; White KD; Eiseman JL
Cancer Chemother Pharmacol; 2003 Aug; 52(2):139-46. PubMed ID: 12761648
[TBL] [Abstract][Full Text] [Related]
4. Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice.
Xu L; Eiseman JL; Egorin MJ; D'Argenio DZ
J Pharmacokinet Pharmacodyn; 2003 Jun; 30(3):185-219. PubMed ID: 14571691
[TBL] [Abstract][Full Text] [Related]
5. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.
Ramanathan RK; Trump DL; Eiseman JL; Belani CP; Agarwala SS; Zuhowski EG; Lan J; Potter DM; Ivy SP; Ramalingam S; Brufsky AM; Wong MK; Tutchko S; Egorin MJ
Clin Cancer Res; 2005 May; 11(9):3385-91. PubMed ID: 15867239
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations.
Egorin MJ; Rosen DM; Wolff JH; Callery PS; Musser SM; Eiseman JL
Cancer Res; 1998 Jun; 58(11):2385-96. PubMed ID: 9622079
[TBL] [Abstract][Full Text] [Related]
7. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.
Banerji U; O'Donnell A; Scurr M; Pacey S; Stapleton S; Asad Y; Simmons L; Maloney A; Raynaud F; Campbell M; Walton M; Lakhani S; Kaye S; Workman P; Judson I
J Clin Oncol; 2005 Jun; 23(18):4152-61. PubMed ID: 15961763
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
9. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
Lee CK; Rowinsky EK; Li J; Giles F; Moore MJ; Hidalgo M; Capparelli E; Jolivet J; Baker SD
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2158-65. PubMed ID: 16609029
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of the novel anticancer agent KRN7000.
Crul M; Mathôt RA; Giaccone G; Punt CA; Rosing H; Hillebrand MX; Ando Y; Nishi N; Tanaka H; Schellens JM; Beijnen JH
Cancer Chemother Pharmacol; 2002 Apr; 49(4):287-93. PubMed ID: 11914907
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.
Chung YL; Troy H; Banerji U; Jackson LE; Walton MI; Stubbs M; Griffiths JR; Judson IR; Leach MO; Workman P; Ronen SM
J Natl Cancer Inst; 2003 Nov; 95(21):1624-33. PubMed ID: 14600095
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic model of PI-88, a heparanase inhibitor.
Hudachek SF; Eckhardt SG; Hicks B; Gustafson DL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):743-53. PubMed ID: 19633850
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma.
Johnston JS; Phelps MA; Blum KA; Blum W; Grever MR; Farley KL; Dalton JT
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Aug; 871(1):15-21. PubMed ID: 18635408
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
Latz JE; Chaudhary A; Ghosh A; Johnson RD
Cancer Chemother Pharmacol; 2006 Apr; 57(4):401-11. PubMed ID: 16322991
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy.
Faltaos DW; Hulot JS; Urien S; Morel V; Kaloshi G; Fernandez C; Xuan kH; Leblond V; Lechat P
Cancer Chemother Pharmacol; 2006 Nov; 58(5):626-33. PubMed ID: 16528531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
